S. Takahashi

发表

Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women.

S. Nishimura, K. Tada, M. Makita, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels.

K. Hatake, K. Aiba, S. Takahashi, 2003, Endocrine-related cancer.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka, H. Shimodaira, S. Morita, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.

M. Kodaira, Y. Mishima, T. Saotome, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral Fluoroprimidine Based Chemotherapy of HER2 Positive Gastric Cancer

Y. Taura, H. Akashi, S. Takahashi, 2017 .

Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer

Tomomi Sato, T. Sato, M. Yanagi, 2008, Cancer Chemotherapy and Pharmacology.

Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer.

M. Koizumi, S. Takahashi, A. Aruga, 1997, British Journal of Cancer.

Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib

Y. Kato, Y. Mishima, K. Takeuchi, 2006, Targeted Oncology.

Bone metabolic markers in bone metastasis of breast cancer

M. Koizumi, S. Takahashi, E. Ogata, 1999, International Journal of Clinical Oncology.

Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.

M. Koizumi, S. Matsumoto, S. Takahashi, 1999, Clinical nuclear medicine.

Title Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer : a multicenter , randomized , double-blind , placebo-controlled , parallel-group phase II study

T. Ogawa, K. Matsuura, K. Okami, 2018 .

Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

T. Fujii, Kaoru Tanaka, T. Ogawa, 2017, BMC Cancer.

Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer

Y. Tanigawara, M. Nakane, T. Saotome, 2001, International Journal of Clinical Oncology.

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

G. Wakabayashi, M. Unno, I. Hyodo, 2015, British Journal of Cancer.

Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline.

M. Nakane, K. Kage, I. Fukui, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

J. Furuse, P. Bycott, T. Okusaka, 2015, Japanese journal of clinical oncology.

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

T. Yamanaka, K. Muro, A. Homma, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, Lei Zhou, A. Stopeck, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, A. Stopeck, C. Barrios, 2012 .

Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.

S. Matsumoto, T. Shimoji, K. Nakano, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.

D. Ennishi, M. Tanimoto, R. Suzuki, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer

Y. Yamada, K. Aiba, S. Takahashi, 2000, International Journal of Clinical Oncology.

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.

D. Ennishi, M. Tanimoto, S. Sakajiri, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload

A. Bankier, A. Gemma, H. Iwata, 2019, Poster Session Abstracts.

92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

H. Iwata, C. Powell, S. Verma, 2021 .

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

S. Kato, Kazunori Otsuka, H. Shibata, 2009, British Journal of Cancer.

Cancer vaccines.

M. Brenner, R. Rousseau, S. Takahashi, 2001, Hematology/Oncology Clinics of North America.

Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.

M. Kodaira, T. Saotome, K. Takeuchi, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

995PDPHASE II STUDY OF LENVATINIB (LEN), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ALL HISTOLOGIC SUBTYPES OF ADVANCED THYROID CANCER (DIFFERENTIATED, MEDULLARY AND ANAPLASTIC).

K. Nakano, M. Tahara, H. Minami, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors.

N. Boku, S. Hironaka, K. Yamazaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study

C. Redfern, H. Iwata, S. Modi, 2019, Poster Session Abstracts.